Loading…
Cue Biopharma, Inc. is projected to decline to $23.39 by 2027, a -13% move from its current price of $26.84. CUE is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $25.11 | $26.84 | $28.70 | +0.01% |
| Aug 5 | $24.43 | $26.85 | $29.51 | +0.03% |
| Aug 6 | $23.92 | $26.85 | $30.15 | +0.04% |
| Aug 7 | $23.49 | $26.85 | $30.69 | +0.05% |
| Aug 8 | $23.13 | $26.86 | $31.19 | +0.07% |
| Aug 9 | $22.80 | $26.86 | $31.64 | +0.08% |
| Aug 10 | $22.51 | $26.86 | $32.06 | +0.09% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $22.51 | $26.86 | $32.06 | +0.09% |
| Week 2 | $20.94 | $26.89 | $34.53 | +0.18% |
| Week 3 | $19.81 | $26.91 | $36.56 | +0.27% |
| Week 4 | $18.91 | $26.94 | $38.37 | +0.36% |
| Week 5 | $18.16 | $26.96 | $40.04 | +0.46% |
| Week 6 | $17.50 | $26.99 | $41.62 | +0.55% |
| Week 7 | $16.92 | $27.01 | $43.12 | +0.64% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cue Biopharma, Inc. is a clinical-stage therapeutics company focused on developing therapies for immunological disorders.
Its lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action, currently in Phase 2 development for allergic diseases. The company also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation.
Cue Biopharma's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program advancing toward Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc.
in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Cue Biopharma, Inc. trades under the symbol CUE in the Healthcare sector. The current price is $26.84 and the market capitalization is $112.74M, with a market rank of 4093.
The forecast trajectory shows a near-term range and a long-term bullish path. In 2026, the avg price is $26.84 with a neutral outlook, then the trend broadens with bullish momentum in 2029–2050 as the avg price rises to $32.58 in 2029, $37.03 in 2030, $80.34 in 2040, and $189.04 in 2050, with max forecasts up to $64.13 (2030) and $434.80 (2050).
A major floor 80.2% below — a decisive break under it would weaken the trend.
The nearest floor, 5.4% below — buyers have tended to step in here.
The nearest ceiling, 37.0% above — a clean break opens room to run.
A major ceiling 53.0% above — clearing it would confirm fresh momentum.
Key CUE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CUE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $29.61 | Sell | $29.26 | Sell |
| MA 10 | $31.19 | Sell | $30.25 | Sell |
| MA 20 | $31.80 | Sell | $30.50 | Sell |
| MA 50 | $28.38 | Sell | $28.31 | Sell |
| MA 100 | $22.24 | Buy | $24.48 | Buy |
| MA 200 | $18.14 | Buy | $22.02 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.25 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -150.81 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.72 | Sell |
| ROC (12) | -5.79 | Sell |
| Bollinger %B (20,2) | 0.04 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.45 | Buy |
| Awesome (5,34) | -0.35 | Sell |
| Ultimate (7,14,28) | 30.89 | Neutral |
| Momentum (10) | -4.32 | Sell |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 27.76 | Sell |
| ADX (14) | 10.74 | Neutral |
| ATR (14) | 1.91 | Info |
The 30-day technical picture is NEUTRAL.
RSI14 is 40, and the stock sits near-term around the SMA50 of $28.38, with the SMA200 at $18.14.
Support is at $25.39 and resistance at $36.78, with a 30-day price range of $17.28 to $41.70. Annualized volatility is listed at 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.31 | $26.84 | $36.17 | 0% | Neutral | |
| $17.04 | $23.39 | $34.70 | -13% | Neutral | |
| $17.46 | $25.48 | $40.33 | -5% | Neutral | |
| $21.21 | $32.63 | $54.26 | +22% | Bullish | |
| $22.94 | $37.01 | $64.08 | +38% | Bullish | |
| $28.04 | $47.29 | $84.78 | +76% | Bullish | |
| $28.87 | $50.79 | $93.91 | +89% | Bullish | |
| $24.19 | $44.32 | $84.25 | +65% | Bullish | |
| $25.32 | $48.25 | $94.04 | +80% | Bullish | |
| $22.94 | $45.44 | $90.63 | +69% | Bullish | |
| $36.06 | $80.14 | $175.74 | +199% | Bullish | |
| $85.28 | $189.52 | $435.90 | +606% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $5.31 | $26.84 | $34.83 | +0.00% |
| September 2026 | $22.49 | $27.35 | $34.70 | +1.88% |
| October 2026 | $22.03 | $27.16 | $35.17 | -0.68% |
| November 2026 | $22.57 | $28.15 | $37.04 | +3.63% |
| December 2026 | $21.50 | $27.10 | $36.17 | -3.73% |
Click any year to see its month-by-month CUE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect CUE to range from $5.31 to $36.17 through 2026. The $26.84 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The CUE price prediction for 2027 points to an average of $23.39 (low $17.04, high $34.70) — a potential decline of -13% on today's $26.84. A consolidation phase looks the most probable path here.
In 2028, CUE is projected to trade between $17.46 and $40.33, averaging $25.48 — a potential decline of -5% from today's $26.84. That is up +9% on the projected 2027 average. Price action looks broadly range-bound.
Cue Biopharma, Inc.'s 2029 outlook centres on $32.63, within a $21.21 to $54.26 range. That is up +28% on the projected 2028 average. That marks a +22% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, CUE could reach as high as $64.08, with a base case around $37.01 and support toward $22.94 — roughly +38% from $26.84. Momentum favours further upside here.
Expect CUE to range from $28.04 to $84.78 through 2031. The $47.29 average target implies a +76% move from current prices. That is up +28% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The CUE price prediction for 2032 points to an average of $50.79 (low $28.87, high $93.91) — a potential gain of +89% on today's $26.84. Momentum favours further upside here.
In 2033, CUE is projected to trade between $24.19 and $84.25, averaging $44.32 — a potential gain of +65% from today's $26.84. That is -13% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
Cue Biopharma, Inc.'s 2034 outlook centres on $48.25, within a $25.32 to $94.04 range. That is up +9% on the projected 2033 average. That marks a +80% change versus current levels. Momentum favours further upside here.
By 2035, CUE could reach as high as $90.63, with a base case around $45.44 and support toward $22.94 — roughly +69% from $26.84. Buyers look set to stay in control over this stretch.
Expect CUE to range from $36.06 to $175.74 through 2040. The $80.14 average target implies a +199% move from current prices. That is up +76% on the projected 2035 average. Momentum favours further upside here.
The CUE price prediction for 2050 points to an average of $189.52 (low $85.28, high $435.90) — a potential gain of +606% on today's $26.84. Buyers look set to stay in control over this stretch.
Investing $1,000 in CUE today (≈ 37.257824 CUE) could be worth
$7,061.12
+$6,061.12 (+606%) by 2050 · US Dollar
Based on the average projected CUE price of $189.52 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CUEwould be worth at today's price.
$1,000 invested in CUE on Jul 31, 2025 (≈ 44.385263 CUE) would be worth
$1,191.3
+$191.3 (+19.1%) today · 1.19× · US Dollar
Based on a CUE entry price of $22.53 vs. today's $26.84.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $32.12 | $835.62 | -16.4% |
| 1 month ago | $28.34 | $947.07 | -5.3% |
| 3 months ago | $30.42 | $882.31 | -11.8% |
| 6 months ago | $10.2 | $2,631.37 | +163.1% |
| 1 year ago | $22.53 | $1,191.3 | +19.1% |
| All time (5.0y) ago | $310.5 | $86.44 | -91.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CUE forecast.
Our base-case forecast reaches $54.00 around 2040.
Implied market cap at $54.00: $226.82M
The multi-year outlook shows a bullish trajectory beginning in 2029, with the 2029 avg price at $32.58 and a bullish sentiment. In 2030, the avg price is $37.03 with a 38% ROI, and the sentiment remains BULLISH.
By 2040, the avg price is $80.34 with a 199.3% ROI, continuing the bullish path into 2050 where the avg price is $189.04 and the ROI reaches 604.3%. The forecasts imply substantial upside from the 2029–2030 window through 2050, albeit with the usual inherent uncertainty of early-stage therapeutics and milestone-driven developments. Key drivers referenced include CUE-221 in Phase 2 for allergic diseases and CUE-401 advancing toward Phase 1, along with the Immuno-STAT platform’s approach.
Risks include the inherent uncertainty of clinical progress and regulatory outcomes, which can affect actual results versus forecasts.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $37.03 with a max of $64.13 and a min of $22.96, representing a 38% ROI and a bullish sentiment.
Forecasts indicate a bullish sentiment from 2029 onward, with an average price rising to $37.03 by 2030, $80.34 by 2040, and $189.04 by 2050 (ROI 38%, 199.3%, and 604.3%, respectively). These are estimates, not guarantees.
Yes, according to the forecast, the max price by 2050 is $434.80, with $176.20 as a max in 2040, indicating potential to exceed $100 over the long term.
Current price is $26.84 and market cap is $112.74M.
The 30-day range is from $17.28 to $41.70.
Cue Biopharma, Inc. Community Discussion
0Share your Cue Biopharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.